Autosomal recessive severe congenital neutropenia (SCN) due to C-X-C motif chemokine receptor 2 (CXCR2) deficiency is a very rare, inherited immune disorder. Babies are born with very low neutrophil counts (a type of white blood cell that fights bacteria and fungi). Because the body cannot move neutrophils properly from the bone marrow into the blood and to infection sites, affected children get frequent, sometimes severe infections early in life. The condition is autosomal recessive, which means the child inherits a non-working copy of the CXCR2 gene from each parent. orpha.net+1

The CXCR2 protein sits on the surface of neutrophils and acts like a GPS receiver. It “listens” to chemical signals (chemokines such as IL-8/CXCL8) and guides neutrophils out of the marrow and toward germs. When both copies of CXCR2 are damaged (loss-of-function mutations), that guidance system fails; neutrophils don’t traffic normally, so bacterial infections become much more likely. Recent reports show biallelic CXCR2 mutations define a distinct form of congenital neutropenia with mechanisms different from other neutropenia syndromes. UniProt+2PMC+2

This is a rare, inherited immune disorder. Babies are born with very low neutrophils, the white blood cells that fight bacteria. The cause is harmful changes in the CXCR2 gene. CXCR2 is a receptor that helps mature neutrophils leave the bone marrow and enter the blood. When CXCR2 does not work, neutrophils are “trapped” in the marrow. Blood tests show severe neutropenia from early life. Children get repeated, serious bacterial infections unless treated. Doctors classify it among “severe congenital neutropenia (SCN).” Genetic testing confirms the diagnosis. Management often uses G-CSF (to raise counts), strict infection-prevention, and—in selected cases—stem-cell transplant. PMC+2orpha.net+2

WHIM syndrome (CXCR4 gain-of-function) also causes neutropenia and marrow retention (myelokathexis). But WHIM is a different pathway (CXCR4), often with warts and low antibodies. CXCR2-SCN lacks those classic WHIM features and shows biallelic CXCR2 variants. The shared theme is poor neutrophil egress from marrow. ASH Publications+1

Other names

Doctors and databases may use any of these labels for the same condition:

• Autosomal recessive severe congenital neutropenia due to CXCR2 deficiency (preferred clinical name). orpha.net

• Biallelic CXCR2 loss-of-function congenital neutropenia (describes the genetic mechanism). PMC

• CXCR2-related primary immunodeficiency with neutropenia (emphasizes it is a primary immune disorder). rarediseases.info.nih.gov

• MONDO:0018487 (CXCR2-related SCN) (ontology term used in bioinformatics). ebi.ac.uk

Types

There isn’t a formal list of “types,” but doctors see a spectrum:

1. Classic severe, persistent neutropenia. Very low absolute neutrophil count (ANC) in infancy with repeated bacterial infections. orpha.net

2. Moderate/variable neutropenia. ANC may be low but not always extreme; infections still occur because neutrophils don’t migrate well. PMC

3. Phenotypes overlapping other SCN genes (differential diagnosis). Patients can look similar to ELANE or HAX1 SCN clinically, so gene testing is essential to separate them. PMC+1

4. Families with newly reported CXCR2 variants. Recent studies identified additional families and expanded the range of clinical features, confirming CXCR2 deficiency as its own entity. haematologica.org+1

Causes

For this disorder, the root cause is two faulty copies of the CXCR2 gene. The list below explains the main biological causes and contributors that create the disease picture or make it worse:

1. Biallelic CXCR2 loss-of-function variants. The direct genetic cause—both gene copies carry harmful changes. PMC

2. Missense or truncating CXCR2 mutations. Different mutation types can break receptor signaling or surface expression. PMC

3. Defective neutrophil chemotaxis toward CXCR2 ligands (e.g., IL-8/CXCL8). Cells can’t follow chemokine trails. UniProt

4. Impaired neutrophil egress from bone marrow. Neutrophils are made but don’t exit effectively. PMC

5. Abnormal neutrophil trafficking to infected tissues. Migration to sites of infection is blunted. PMC

6. Autosomal recessive inheritance in consanguineous families. Increases the chance both parents carry the same variant. orpha.net

7. Distinct pathogenesis from CXCR4/WHIM—no compensatory pathway. The biology differs, so CXCR2 defects aren’t rescued by CXCR4 signaling. haematologica.org

8. Bone-marrow neutrophil retention signals outweigh release signals. Without CXCR2, “go” signals are weak. (Inferred from mechanistic studies of CXCR2 function.) UniProt

9. Reduced responsiveness to inflammatory chemokines in tissues. Infections progress because neutrophils don’t arrive on time. UniProt

10. Developmental vulnerability of infants. Babies with SCN are hit early because neonatal immunity already relies heavily on neutrophils. (General SCN principle.) PMC

11. Potential digenic/background modifiers. Other neutropenia genes sometimes modify disease pictures in SCN cohorts. haematologica.org

12. Misdiagnosis delays (treated as “recurrent infections” only). Late recognition can worsen outcomes until genetic testing is done. PMC

13. Bacterial virulence factors exploiting low neutrophil presence. Severe infections flourish when front-line defense is absent. (SCN principle.) PMC

14. Oral biofilm overgrowth due to chronic neutropenia. Leads to gingivitis/periodontitis. (SCN hallmark). PMC

15. Skin barrier breaches with poor neutrophil response. Cellulitis/abscesses occur more easily. (SCN hallmark). PMC

16. Sinopulmonary pathogen exposure. Repeated sinusitis/otitis/pneumonia in neutropenia. (SCN hallmark). PMC

17. Under-immunization or missed infection prophylaxis. Preventive lapses increase infection risk in primary immunodeficiency. (General PIDD care principle). PMC

18. Inadequate dental hygiene in a high-risk host. Increases oral ulcers and gingival disease severity. (SCN principle). PMC

19. Limited access to early genetic testing. Delays targeted care and surveillance. (Testing recommendations). mayocliniclabs.com

20. Potential pathway cross-talk in inflammation/cancer biology highlighting CXCR2’s central role. Underscores how central CXCR2 is to neutrophil biology when disrupted. Cell

Common symptoms and signs

1. Frequent fevers—the body’s alarm for infection. PMC

2. Mouth ulcers and sore gums (gingivitis). Very typical in neutropenia. NCBI

3. Frequent skin infections like cellulitis or boils (abscesses). PMC

4. Sinus infections (sinusitis) that keep coming back. PMC

5. Ear infections (otitis media), especially in young children. PMC

6. Throat infections (pharyngitis/tonsillitis). NCBI

7. Pneumonia or chest infections, sometimes severe. PMC

8. Poor wound healing or wounds that get infected easily. PMC

9. Swollen lymph nodes in the neck during infections. NCBI

10. Fatigue and low energy during infection spells. PMC

11. Digestive infections (perianal infections, sometimes diarrhea with bacterial causes). PMC

12. Bloodstream infections (sepsis) in severe cases. PMC

13. Dental problems—bleeding gums, early periodontitis. PMC

14. Failure to thrive or poor weight gain when infections are frequent. PMC

15. Recurrent hospitalizations for IV antibiotics due to serious infections. PMC

Diagnostic tests

A) Physical examination (bedside checks)

1. General infection check (fever, vital signs, toxic appearance). Doctors look for fever, fast heart rate, fast breathing, and low blood pressure that suggest serious bacterial illness in a neutropenic child. PMC

2. Head-and-neck exam (ulcers, gum swelling, sinus tenderness, ear findings). Repeated oral and sinus issues raise suspicion for neutropenia. NCBI

3. Skin exam (cellulitis, abscess, wound problems). Typical sites include diaper area, axillae, and hair follicles. PMC

4. Chest exam (cough, crackles). Helps decide if imaging and antibiotics are urgent for pneumonia. PMC

5. Abdomen/perianal exam (tenderness, fissures, perirectal abscess). Perianal infections are a red flag in neutropenia. PMC

B) Manual/office-based tests

6. Manual differential on a blood smear. A lab professional counts white cells by microscope to confirm very low neutrophils and assess cell maturity and morphology. PMC

7. Serial ANC tracking. Repeating complete blood counts (CBCs) over time shows persistent neutropenia, supporting a congenital pattern rather than a temporary drop. PMC

8. Infection diary/fever chart. Simple but useful; frequent bacterial infections align with primary neutropenia. (Clinical practice principle for SCN.) PMC

9. Targeted family assessment for autosomal recessive inheritance. Pedigree review can reveal affected siblings or consanguinity, guiding genetic testing. orpha.net

10. Dental evaluation by visual inspection and probing. Helps document gingivitis/periodontitis typical in chronic neutropenia. PMC

C) Laboratory and pathological tests

11. Complete blood count (CBC) with absolute neutrophil count (ANC). The core test—shows low ANC, often profoundly reduced. PMC

12. Peripheral blood smear review. Looks for left shift, toxic changes, or other cytopenias; helps rule out alternative causes. PMC

13. Bone marrow aspirate/biopsy. In SCN, marrow may show maturation arrest of myeloid cells; essential to exclude other marrow disorders. jcp.bmj.com

14. Genetic testing including CXCR2. A neutropenia gene panel or exome sequencing can detect biallelic CXCR2 mutations and separate this disorder from ELANE, HAX1, G6PC3, and others. mayocliniclabs.com

15. Chemokine signaling/functional assays (research/tertiary centers). Some centers assess neutrophil chemotaxis to CXCR2 ligands to support the mechanism. (Mechanistic context.) PMC

16. Blood cultures and cultures from infected sites. Identify bacteria/fungi during febrile episodes to guide antibiotics. PMC

17. Inflammatory markers (CRP/ESR, procalcitonin). Help track severity of infections in a neutropenic host. PMC

18. Immunology screen to rule out other primary immunodeficiencies. Basic Ig levels and lymphocyte subsets help ensure neutropenia is the main issue. PMC

D) Electrodiagnostic tests

19. Electrodiagnostic studies are not routinely indicated for this hematologic condition. Tests like nerve conduction or EEG/EMG do not diagnose neutropenia; clinicians focus on blood, marrow, genetics, and infection work-ups instead. (Best-practice clarification from SCN literature.) PMC

E) Imaging tests

20. Targeted imaging to look for complications of infection.
    • Chest X-ray/CT for pneumonia or lung abscess;
    • Sinus CT for chronic sinusitis;
    • Ultrasound/CT for deep abscesses;
    • Echocardiography when bloodstream infections suggest endocarditis. Imaging is chosen based on symptoms to find hidden infections in neutropenia. PMC

Non-pharmacological treatments (therapies & other measures)

1. Neutropenic fever emergency plan. Always treat fever as an emergency. Go to hospital if temperature is ≥38.3 °C once or ≥38.0 °C for ≥1 hour. Early antibiotics save lives. Purpose: rapid infection control. Mechanism: fast empiric coverage lowers bacteremia risk in low-neutrophil states. NCBI+1

2. Strict hand hygiene for patient & household. Wash with soap and water or alcohol rub often; ask visitors to clean hands. Purpose: stop germ spread. Mechanism: reduces contact transmission when innate immunity is weak. CDC+1

3. Food safety (“neutropenic diet” principles). Eat properly cooked foods; wash produce well; avoid cross-contamination; refrigerate promptly. Purpose: reduce foodborne infections. Mechanism: lowers exposure to pathogens from raw foods/equipment. Memorial Sloan Kettering Cancer Center

4. Environmental hygiene at home. Clean high-touch surfaces; wear gloves for gardening; avoid cleaning animal waste without protection. Purpose: cut environmental microbes. Mechanism: reduces inoculum that can seed infection. CDC

5. Dental and oral care. Soft toothbrush; dentist-guided care to prevent gingivitis and mouth ulcers that can seed bacteria. Purpose: keep oral barrier intact. Mechanism: lowers mucosal entry points for pathogens. CDC

6. Vaccination with inactivated vaccines per schedule. Keep influenza, pneumococcal, Hib, and routine inactivated vaccines up to date; consult specialists about live vaccines. Purpose: prevent vaccine-preventable disease. Mechanism: primes adaptive immunity even if neutrophils are low. CDC+1

7. Avoid live bacterial vaccines in severe neutropenia. Live bacterial vaccines (e.g., BCG, oral typhoid) are contraindicated; live viral vaccines are individualized. Purpose: avoid vaccine-derived infection. Mechanism: neutrophil defects increase risk from live bacteria. PMC+1

8. Masking and crowd management during outbreaks. Use masks in crowded indoor spaces and avoid sick contacts. Purpose: reduce respiratory pathogen exposure. Mechanism: fewer droplets/aerosols reach mucosa. CDC

9. Skin care and wound vigilance. Daily inspection; prompt cleansing and covering of cuts; avoid shared razors. Purpose: block skin infections. Mechanism: keeps bacterial load low at barrier breaks. PMC

10. Catheter care if a central line is used. Use aseptic technique and proper dressing changes. Purpose: prevent line sepsis. Mechanism: reduces biofilm and entry of skin flora. CDC

11. Household vaccination (“cocooning”). Make sure household members are fully vaccinated (esp. influenza). Purpose: create a protective ring. Mechanism: fewer vectors bringing infections home. Infectious Diseases Society of America

12. Safe pet and gardening practices. Gloves for litter/gardening; avoid reptile pets that shed Salmonella; wash hands after handling animals. Purpose: reduce zoonoses. Mechanism: limits exposure to fecal and soil bacteria. CDC

13. Temperature monitoring tools at home. Keep a working oral thermometer; educate family on thresholds. Purpose: early detection. Mechanism: faster time to hospital antibiotics. NCBI

14. School/daycare infection control. Inform staff; keep child home during outbreaks; emphasize hand hygiene. Purpose: lower exposure to contagious peers. Mechanism: fewer close-contact transmissions. CDC

15. Travel precautions. Avoid destinations with high infectious risk if counts are low; bring records and fever plan. Purpose: mitigate travel-related infections. Mechanism: reduces exposure and delays to care. OUP Academic

16. Showering and daily hygiene routine. Regular showers, gentle soaps, and clean clothes reduce skin bacterial load. Purpose: decrease skin-origin infections. Mechanism: lowers colonization density. PMC

17. Humidified air and nasal care. Maintain nasal moisture to prevent fissures. Purpose: keep mucosal barrier intact. Mechanism: fewer microcracks for bacterial entry. PMC

18. Sun/heat avoidance during profound neutropenia. Prevent skin breakdown and heat rash that can get infected. Purpose: protect barrier. Mechanism: reduces microtrauma risk. PMC

19. Education on red-flag symptoms. Teach to look for chills, mouth sores, painful urination, or new cough even without high fever. Purpose: earlier care. Mechanism: symptoms may be subtle when neutrophils are low. UpToDate

20. Multidisciplinary care and registries. Link with SCN centers to guide G-CSF dosing and transplant timing. Purpose: optimize outcomes and safety. Mechanism: expert protocols lower severe infection and leukemia transformation risk in SCN overall. ASH Publications+1

---

Drug treatments

In CXCR2-SCN, the core drug class is G-CSF/GM-CSF (multiple FDA-approved products; dosing is individualized). Antibiotics are essential during fever (per IDSA/ASCO). CXCR4 antagonists (e.g., mavorixafor) are for WHIM, not CXCR2-SCN, but I note them for mechanism context. Below are key medicines clinicians actually use around SCN care; labels are cited.

1. Filgrastim (e.g., Neupogen; biosimilars: Zarxio, Nivestym, Releuko).
   Class: G-CSF. Dose/Time: Common starting 5 µg/kg/day SC; titrate to ANC goal; chronic SCN may need higher individualized doses. Purpose: Raise neutrophils; prevent severe infections. Mechanism: Binds G-CSF receptor on myeloid progenitors → proliferation, maturation, and mobilization of neutrophils. Side effects: Bone pain, splenomegaly/rare rupture, ARDS, allergic reactions; long-term SCN monitoring needed. FDA Access Data+3FDA Access Data+3FDA Access Data+3

2. Pegfilgrastim (e.g., Neulasta; biosimilars: Udenyca, Fulphila, Ziextenzo, Nyvepria, Stimufend, Fylnetra).
   Class: Long-acting G-CSF. Dose/Time: Often 6 mg SC once per chemo cycle; in SCN, regimens are specialist-directed and off-label schedules may be used to maintain ANC. Purpose/Mechanism: Same as filgrastim but pegylated for longer half-life, easing injections. Side effects: Bone pain, leukocytosis, splenic rupture warning, capillary leak, hypersensitivity. FDA Access Data+3FDA Access Data+3FDA Access Data+3

3. Tbo-filgrastim (Granix).
   Class: G-CSF. Dose/Time: Similar to filgrastim (e.g., 5 µg/kg/day SC). Purpose/Mechanism: Increases neutrophil production and speeds recovery. Side effects: Similar G-CSF class warnings. FDA Access Data

4. Efbemalenograstim alfa (Ryzneuta).
   Class: Long-acting G-CSF (novel). Dose/Time: Per label (fixed SC dosing per cycle in adults; specialist use). Purpose/Mechanism: Prolonged stimulation of neutrophil lineage. Side effects: Class effects (bone pain, splenic issues). FDA Access Data

5. Sargramostim (Leukine).
   Class: GM-CSF. Dose/Time: Individualized SC/IV; used in select contexts (e.g., post-transplant, infection risk). Purpose/Mechanism: Stimulates myeloid recovery (broader than G-CSF). Side effects: Fever, bone pain, edema; labeling cautions. FDA Access Data

6. Empiric broad-spectrum antibiotics for febrile neutropenia (e.g., anti-pseudomonal β-lactams).
   Class: Antibacterials (examples depend on local protocols). Dose/Time: Start within 1 hour of triage; tailor to risk and cultures. Purpose/Mechanism: Rapid bactericidal coverage while ANC is low. Side effects: Drug-specific. PubMed+1

7. Plerixafor (Mozobil) + G-CSF (for stem-cell mobilization when transplant is planned).
   Class: CXCR4 antagonist; HSC mobilizer. Dose/Time: 0.24 mg/kg SC typically the night before apheresis (per label). Purpose: Mobilize stem cells for HSCT collection. Mechanism: Blocks CXCR4–SDF-1 retention, freeing HSCs to blood. Side effects: GI upset, injection reactions; rare anaphylaxis; tumor-cell mobilization warning. FDA Access Data+1

8. Antifungals in high-risk or persistent fever per guidelines (agent varies).
   Class: Antifungals. Dose/Time: Per IDSA/ASCO risk pathways. Purpose/Mechanism: Preempt or treat invasive fungal disease in prolonged neutropenia. Side effects: Agent-specific. Infectious Diseases Society of America

9. Antivirals when indicated (e.g., influenza, HSV) per guideline pathways.
   Class: Antivirals. Dose/Time: Based on pathogen/exposure. Purpose: Shorten illness and complications when innate defense is low. Mechanism: Inhibit viral replication. Infectious Diseases Society of America

10. Vaccines (inactivated).
    Class: Biologicals (preventive). Use: Seasonal influenza, pneumococcal, Hib, etc. Purpose/Mechanism: Build adaptive immunity despite neutrophil deficit. Notes: Live bacterial vaccines contraindicated; live viral vaccines individualized with specialist input. CDC+1

11. G-CSF biosimilar: Zarxio (filgrastim-sndz).
    Label explicitly includes severe chronic neutropenia; adverse events include bone pain and, in SCN, anemia/epistaxis. Dosing individualized to maintain ANC. FDA Access Data

12. G-CSF biosimilar: Nivestym (filgrastim-aafi).
    Indications include reducing infection incidence; used like filgrastim with similar safety profile. FDA Access Data

13. G-CSF biosimilar: Releuko (filgrastim-ayow).
    Includes chronic administration to reduce SCN sequelae (fever, infections, oral ulcers). FDA Access Data

14. Pegfilgrastim biosimilar: Udenyca (pegfilgrastim-cbqv).
    Class warnings: splenic rupture, ARDS, capillary leak, hypersensitivity. FDA Access Data

15. Pegfilgrastim biosimilar: Fulphila (pegfilgrastim-jmdb).
    Label notes leukocytosis, and capillary leak warning; CBC monitoring recommended. FDA Access Data

16. Pegfilgrastim biosimilar: Stimufend (pegfilgrastim-fpgk).
    Biosimilar pegfilgrastim; labeling covers use, handling, and warnings. FDA Access Data+1

17. Pegfilgrastim originator: Neulasta (pegfilgrastim).
    Long-acting G-CSF backbone product; same class warnings. FDA Access Data

18. Filgrastim originator: Neupogen.
    Foundational short-acting G-CSF label with SCN experience. FDA Access Data

19. GM-CSF: Sargramostim (Leukine).
    Alternative myeloid growth factor in selected settings; label safety per FDA. FDA Access Data

20. Efbemalenograstim (Ryzneuta) long-acting G-CSF (repeat for completeness).
    Newer long-acting option with class effects; specialist selection. FDA Access Data

Important: Drug choice, dose, and schedule for congenital neutropenia are specialist decisions. G-CSF is the mainstay in SCN and reduces sepsis risk; HSCT is considered for G-CSF-refractory disease. ASH Publications+1

---

Dietary molecular supplements

1. Copper (if deficient). Copper lack can cause neutropenia and anemia. Repletion (IV or oral) can normalize counts in weeks. Dose is individualized to labs (often 2–4 mg/day orally; IV in severe cases), with monitoring to avoid toxicity. Mechanism: restores enzymes needed for hematopoiesis and neutrophil function. PMC+2med.virginia.edu+2

2. Vitamin B12 (if deficient). B12 deficiency impairs DNA synthesis, reduces neutrophil number and function, and is reversible with supplementation (IM or high-dose oral). Mechanism: restores thymidylate synthesis and marrow proliferation. ASH Publications+1

3. Folate (if deficient). Folate repletion corrects cytopenias and resolves hypersegmented neutrophils within ~10–14 days. Mechanism: 1-carbon transfer reactions for DNA synthesis. NCBI

4. Zinc (avoid deficiency/excess). Zinc supports numerous immune enzymes and cell signaling. Typical RDA ~8–11 mg/day adults; avoid chronic intakes >40 mg/day (UL) due to copper depletion. Mechanism: cofactor for DNA/protein synthesis and immune cell function. Office of Dietary Supplements

5. Vitamin C (adequate intake). Supports epithelial barriers and phagocyte function; improves non-heme iron absorption. Typical adult RDA 75–90 mg/day. Mechanism: antioxidant and cofactor roles in immune defense. Office of Dietary Supplements

6. Vitamin D (correct insufficiency). Vitamin D modulates innate and adaptive immunity; correction may improve neutrophil function and inflammatory balance. Dose per local guidelines and serum 25-OH D. Mechanism: VDR-mediated gene regulation. PMC+1

7. Omega-3 fatty acids (EPA/DHA). Omega-3s incorporate into neutrophil membranes and can modulate neutrophil activation pathways; use food-first (fish) or supplements per clinician. Mechanism: alters lipid mediators and transcription factors. PubMed+1

8. Protein/energy optimization. Adequate calories and protein support marrow output and wound healing. Mechanism: supplies amino acids and energy for hematopoiesis. PMC

9. Iron (only if deficient). Iron deficiency can impair immunity; correct documented deficiency with monitored dosing. Mechanism: cofactor for enzymes and immune cell energy metabolism. Office of Dietary Supplements

10. Probiotic foods caution. In severe neutropenia, avoid high-risk probiotic products due to rare bacteremia/fungemia reports; discuss with your team. Mechanism: avoids translocation risk when barriers/inflammation are altered. Infectious Diseases Society of America

---

Immunity-supporting / regenerative / stem-cell–related” drugs

1. Filgrastim (G-CSF). Daily SC dosing titrated to ANC; stimulates neutrophil production and function. Foundation drug in SCN. Monitor for bone pain and splenic enlargement. FDA Access Data

2. Pegfilgrastim (long-acting G-CSF). Less frequent injections; similar mechanism and cautions. Used when appropriate per specialist. FDA Access Data

3. Sargramostim (GM-CSF). Broader myeloid stimulation; selected contexts (e.g., post-transplant). Monitor edema/fever. FDA Access Data

4. Plerixafor (CXCR4 antagonist). Used with G-CSF to mobilize stem cells before autologous collection for HSCT if needed. FDA Access Data

5. Efbemalenograstim (long-acting G-CSF). Extended support for neutrophil lineage; dosing per label. FDA Access Data

6. Vaccines (inactivated) as immune risk reducers. Not a “booster” in the supplement sense, but critical for reducing infection risk in neutropenia. Coordinate schedules with specialists. CDC

---

Surgeries / procedures

1. Hematopoietic stem-cell transplantation (HSCT). Procedure to replace marrow with healthy donor cells when SCN is refractory to G-CSF or complicated. Why: Offers cure of the hematopoietic defect; chosen after expert review of risks/benefits. ScienceDirect+1

2. Central venous catheter placement (and removal if infected). Why: Reliable access for antibiotics, transfusions, and G-CSF in some cases; remove if source of bacteremia. CDC

3. Incision and drainage of abscesses. Why: Source control when pus collections arise (skin/soft tissue), because neutrophil-poor hosts need mechanical drainage plus antibiotics. OUP Academic

4. Functional endoscopic sinus surgery (selected). Why: For chronic or refractory bacterial sinusitis causing repeated fevers despite therapy. Infectious Diseases Society of America

5. Dental procedures (e.g., abscess drainage, extraction). Why: Remove infected sources in the mouth that can seed bloodstream infections. CDC

---

Preventions

1. Annual inactivated influenza vaccine. 2) Pneumococcal/Hib per schedule. 3) Strict hand hygiene for everyone in the home. 4) Food safety and avoid raw meats/eggs/sushi. 5) Prompt fever plan and hospital access. 6) Dental care and daily oral hygiene. 7) Avoid live bacterial vaccines; ask about live viral vaccines. 8) Crowd and sick-contact avoidance; masks during outbreaks. 9) Catheter care if applicable. 10) Household cocooning (family fully vaccinated). Infectious Diseases Society of America+5CDC+5CDC+5

---

When to see doctors

Urgent—go now: Fever ≥38.3 °C once or ≥38.0 °C for ≥1 hour; shaking chills; shortness of breath; chest pain; confusion; very sore throat or mouth ulcers that stop eating; painful urination; new abdominal pain; any rapidly spreading skin redness or abscess; central-line redness or pus. These signs can signal sepsis in neutropenia. NCBI

Soon (24–48 h): Mild cold symptoms that persist, new sinus pain, non-healing skin breaks, prolonged diarrhea, or medication side effects (e.g., severe bone pain with G-CSF). Infectious Diseases Society of America

Routine: Vaccination review, growth/side-effect check on G-CSF, dental cleanings, nutrition reviews, and periodic transplant consultations if doses keep escalating. ASH Publications

---

What to eat and what to avoid

Eat (safe choices):

1. Well-cooked meats/fish;

2. Pasteurized dairy;

3. Washed/cooked vegetables

4. Washed/cut fruits you peel yourself;

5. Freshly cooked grains/legumes. Rinse produce well, use separate cutting boards, chill leftovers fast. Memorial Sloan Kettering Cancer Center

Avoid (high-risk items):

1. Raw/undercooked meats, fish, eggs (no sushi/rare burgers);

2. Unpasteurized milk/juices/soft cheeses;

3. Salad bars/buffets with poor temperature control;

4. Unwashed raw sprouts;

5. Deli meats unless heated to steaming. Memorial Sloan Kettering Cancer Center

---

FAQs

1. Is CXCR2-SCN curable? Some patients do very well long-term on G-CSF. HSCT can be curative when indicated. ASH Publications+1

2. Why are neutrophils low if the marrow makes them? Faulty CXCR2 keeps neutrophils from exiting marrow into blood. PMC

3. Does G-CSF fix the gene? No; it stimulates production/release to maintain safe ANC. PMC

4. Are infections still possible with a “normal” ANC on G-CSF? Risk drops, but vigilance is still needed. ASH Publications

5. What’s the danger temperature? ≥38.3 °C once or ≥38.0 °C for ≥1 hour. Go to hospital immediately. NCBI

6. Can we use live vaccines? Avoid live bacterial vaccines; live viral vaccines require specialist input. Inactivated vaccines recommended. PMC+1

7. Do supplements raise neutrophils? Only when a true deficiency exists (e.g., copper, B12, folate). Test first; don’t self-dose. PMC+1

8. Is mavorixafor (Xolremdi) for this disease? It targets CXCR4 (for WHIM syndrome), not CXCR2-SCN. Reuters

9. Can my child attend school? Yes, with infection-control steps and a fever plan. CDC

10. Why bone pain on G-CSF? Rapid marrow expansion stimulates periosteum; usually manageable. FDA Access Data

11. Are long-acting G-CSF shots better? They’re more convenient for some; choice depends on response and side effects. FDA Access Data

12. When consider HSCT? When G-CSF can’t maintain safe counts or infections remain severe. ScienceDirect

13. Do we need home antibiotics “just in case”? Not for routine use; but immediate hospital antibiotics are essential during fever. Follow your center’s plan. PubMed

14. What ANC is “severe” neutropenia? ANC <500/µL (or expected to drop below). U.S. Pharmacist

15. Who should coordinate care? A hematologist/immunologist with congenital neutropenia expertise; consider registry participation. bloodresearch.or.kr

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 13, 2025.